MA30348B1 - Diagnostics et traitements de tumeurs - Google Patents
Diagnostics et traitements de tumeursInfo
- Publication number
- MA30348B1 MA30348B1 MA31315A MA31315A MA30348B1 MA 30348 B1 MA30348 B1 MA 30348B1 MA 31315 A MA31315 A MA 31315A MA 31315 A MA31315 A MA 31315A MA 30348 B1 MA30348 B1 MA 30348B1
- Authority
- MA
- Morocco
- Prior art keywords
- tumors
- diagnostics
- treatments
- methods
- diagnosing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Diagnostics et traitements de tumeurs L'invention concerne des procédés permettant de traiter le cancer par des thérapies de combinaison qui comportent des anticorps anti-VEGF. L'invention concerne également des procédés permettant de diagnostiquer des tumeurs résistantes.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78772006P | 2006-03-29 | 2006-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30348B1 true MA30348B1 (fr) | 2009-04-01 |
Family
ID=38564192
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31315A MA30348B1 (fr) | 2006-03-29 | 2008-10-20 | Diagnostics et traitements de tumeurs |
Country Status (19)
Country | Link |
---|---|
US (2) | US20070264193A1 (fr) |
EP (1) | EP1999151A2 (fr) |
JP (1) | JP2009531463A (fr) |
KR (1) | KR20080106946A (fr) |
CN (1) | CN101448856A (fr) |
AR (1) | AR060228A1 (fr) |
AU (1) | AU2007233237A1 (fr) |
BR (1) | BRPI0709425A2 (fr) |
CA (1) | CA2647430A1 (fr) |
CL (1) | CL2007000876A1 (fr) |
CR (1) | CR10325A (fr) |
IL (1) | IL193842A0 (fr) |
MA (1) | MA30348B1 (fr) |
MX (1) | MX2008012279A (fr) |
NO (1) | NO20084546L (fr) |
RU (1) | RU2008142775A (fr) |
TW (1) | TW200806322A (fr) |
WO (1) | WO2007115045A2 (fr) |
ZA (1) | ZA200807590B (fr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
WO2006094014A2 (fr) | 2005-02-28 | 2006-09-08 | The Regents Of The University Of California | Methodes pour diagnostiquer et pour traiter un cancer endometrique |
US8318906B2 (en) | 2005-04-15 | 2012-11-27 | The Regents Of The University Of California | EMP2 antibodies and their therapeutic uses |
EP1790664A1 (fr) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Anticorps monoclonaux contre claudin-18 pour le traitement du cancer |
CA2678218A1 (fr) * | 2007-02-21 | 2008-08-28 | Ablynx N.V. | Sequences d'acides amines dirigees contre le facteur de croissance de l'endothelium vasculaire et polypeptides comprenant ces sequences, pour le traitement de troubles et de maladies se caracterisant par une angiogenese pathologique ou une neovascularisation |
WO2011063161A2 (fr) | 2009-11-20 | 2011-05-26 | The Regents Of The University Of California | Protéine 2 de membrane épithéliale (emp2) et vitréorétinopathie proliférative (pvr) |
EP3115469B1 (fr) * | 2007-11-19 | 2020-04-29 | Celera Corporation | Marqueurs du cancer du poumon et utilisations de ceux-ci |
WO2009075768A2 (fr) * | 2007-12-07 | 2009-06-18 | Children's Hospital Of Orange County | Dispositif et procédé optiques pour essai de chémosensibilité en temps réel |
WO2009108360A2 (fr) * | 2008-02-29 | 2009-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition de la croissance tumorale post-radique |
WO2010017083A1 (fr) * | 2008-08-04 | 2010-02-11 | Wayne State University | Procédés de traitement du cancer par des anticorps cd11b |
BRPI0912927A2 (pt) * | 2008-08-29 | 2019-10-01 | Genentech Inc | "método de detectar um tumor independente de vegf em um indivíduo e método de tratar um tumor independente de vegf em um indivíduo" |
WO2010046889A1 (fr) * | 2008-10-23 | 2010-04-29 | Quark Pharmaceuticals, Inc. | Procédés de distribution d'arnsi à des cellules de moelle osseuse et leurs utilisations |
EP2379059A4 (fr) * | 2008-12-10 | 2012-10-31 | Anhui Zhongren Technology Co Ltd | Composition à libération contrôlée |
KR101596539B1 (ko) * | 2008-12-23 | 2016-02-22 | 제넨테크, 인크. | 암 환자에서의 진단 목적용 방법 및 조성물 |
US7615353B1 (en) | 2009-07-06 | 2009-11-10 | Aveo Pharmaceuticals, Inc. | Tivozanib response prediction |
MX2012001306A (es) * | 2009-07-31 | 2012-02-28 | Genentech Inc | Inhibicion de matastasis de tumor. |
JP2013501526A (ja) * | 2009-08-14 | 2013-01-17 | ジェネンテック, インコーポレイテッド | Vegfアンタゴニストに対する患者の応答をモニターするための生物学的マーカー |
US7736861B1 (en) | 2009-10-19 | 2010-06-15 | Aveo Pharmaceuticals, Inc. | Tivozanib response prediction |
EP2536432B1 (fr) * | 2010-02-19 | 2018-08-08 | Cornell University | Procédé pour traiter des maladies démyélinisantes auto-immunes et d'autres maladies auto-immunes ou inflammatoires |
WO2011103599A2 (fr) * | 2010-02-19 | 2011-08-25 | The Regents Of The Universith Of California | Réactifs de liaison de la protéine membranaire épithéliale 2 (emp2) et leurs utilisations thérapeutiques dans des maladies oculaires |
KR101313184B1 (ko) * | 2010-06-24 | 2013-09-30 | 한국표준과학연구원 | 질병 지표 검출 키트 및 질병 지표 검출 방법 |
WO2013025944A1 (fr) * | 2011-08-17 | 2013-02-21 | Genentech, Inc. | Inhibition de l'angiogenèse dans les tumeurs réfractaires |
WO2013167153A1 (fr) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Anticorps utiles dans le diagnostic du cancer |
RU2502471C9 (ru) * | 2012-08-21 | 2015-04-20 | Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью населения") | Способ оценки соответствия размеров селезенки норме или отклонению от нее у детей методом ультразвуковой диагностики |
EP2741086A1 (fr) * | 2012-12-06 | 2014-06-11 | Ludwig Boltzmann Gesellschaft | Procédé pour mesurer la coagulation d'échantillons de sang à l'aide de tests visco-élastiques (VET) |
WO2014127785A1 (fr) * | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer |
WO2014159923A1 (fr) * | 2013-03-13 | 2014-10-02 | Health Research, Inc. | Amélioration de vaccins |
RU2546105C1 (ru) * | 2014-04-29 | 2015-04-10 | Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью населения") | Способ оценки методом ультразвуковой диагностики соответствия размеров селезенки норме или отклонению от нее у детей от 3 до 15 лет |
WO2018078158A1 (fr) * | 2016-10-31 | 2018-05-03 | Hexal Ag | Préparation d'anticorps |
EP3826683A4 (fr) * | 2018-07-24 | 2022-04-13 | So Young Life Sciences Corporation | Utilisation de liposomes permettant la transmission d'une protéine et d'un gène codant pour la protéine à une cellule vivante |
US20200347449A1 (en) * | 2019-05-01 | 2020-11-05 | The Broad Institute, Inc. | Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells |
CN112946291A (zh) * | 2019-12-10 | 2021-06-11 | 上海交通大学医学院附属仁济医院 | Fgf18在制备诊断和预测卵巢癌试剂中的应用及fgf18化学发光检测试剂盒 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4840793A (en) * | 1987-06-11 | 1989-06-20 | Dana-Farber Cancer Institute | Method of reducing tissue damage at an inflammatory site using a monoclonal antibody |
US6582959B2 (en) * | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
US20030206899A1 (en) * | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
US20020032313A1 (en) * | 1991-03-29 | 2002-03-14 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
WO1994004679A1 (fr) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
DE4422551C1 (de) * | 1994-06-28 | 1995-07-27 | Daimler Benz Ag | Durch Servomotor unterstützte Zahnstangenlenkung |
US5871697A (en) * | 1995-10-24 | 1999-02-16 | Curagen Corporation | Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing |
US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US20020032315A1 (en) * | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
PT1325932E (pt) * | 1997-04-07 | 2005-06-30 | Genentech Inc | Anticorpos anti-vegf |
AU4972900A (en) * | 1999-04-08 | 2000-11-14 | Arch Development Corporation | Use of anti-vegf antibody to enhance radiation in cancer therapy |
US6703020B1 (en) * | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
BR0111861A (pt) * | 2000-06-23 | 2003-12-23 | Schering Ag | Combinações e composições que interferem com função receptora vegf/vegf e angiopoietina/tie e seu uso(ii) |
AU2003215163A1 (en) * | 2002-02-12 | 2003-09-04 | Vanderbilt University | Inhibition of vegf receptor signaling reverses tumor resistance to radiotherapy |
KR20180014881A (ko) * | 2003-05-30 | 2018-02-09 | 제넨테크, 인크. | 항-vegf 항체를 사용한 치료 |
WO2005044853A2 (fr) * | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anticorps anti-vegf |
US20060009360A1 (en) * | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
-
2007
- 2007-03-28 CA CA002647430A patent/CA2647430A1/fr not_active Abandoned
- 2007-03-28 WO PCT/US2007/065377 patent/WO2007115045A2/fr active Application Filing
- 2007-03-28 MX MX2008012279A patent/MX2008012279A/es active IP Right Grant
- 2007-03-28 US US11/692,681 patent/US20070264193A1/en not_active Abandoned
- 2007-03-28 EP EP07759590A patent/EP1999151A2/fr not_active Withdrawn
- 2007-03-28 BR BRPI0709425-6A patent/BRPI0709425A2/pt not_active IP Right Cessation
- 2007-03-28 CN CNA2007800184412A patent/CN101448856A/zh active Pending
- 2007-03-28 RU RU2008142775/14A patent/RU2008142775A/ru not_active Application Discontinuation
- 2007-03-28 JP JP2009503253A patent/JP2009531463A/ja active Pending
- 2007-03-28 ZA ZA200807590A patent/ZA200807590B/xx unknown
- 2007-03-28 AU AU2007233237A patent/AU2007233237A1/en not_active Abandoned
- 2007-03-28 KR KR1020087023600A patent/KR20080106946A/ko not_active Application Discontinuation
- 2007-03-29 TW TW096111126A patent/TW200806322A/zh unknown
- 2007-03-29 CL CL200700876A patent/CL2007000876A1/es unknown
- 2007-03-29 AR ARP070101340A patent/AR060228A1/es not_active Application Discontinuation
-
2008
- 2008-09-02 IL IL193842A patent/IL193842A0/en unknown
- 2008-09-29 CR CR10325A patent/CR10325A/es not_active Application Discontinuation
- 2008-10-20 MA MA31315A patent/MA30348B1/fr unknown
- 2008-10-28 NO NO20084546A patent/NO20084546L/no not_active Application Discontinuation
-
2010
- 2010-04-28 US US12/769,004 patent/US20100239568A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN101448856A (zh) | 2009-06-03 |
BRPI0709425A2 (pt) | 2011-07-12 |
CL2007000876A1 (es) | 2008-02-08 |
WO2007115045A2 (fr) | 2007-10-11 |
EP1999151A2 (fr) | 2008-12-10 |
JP2009531463A (ja) | 2009-09-03 |
CR10325A (es) | 2008-12-03 |
US20070264193A1 (en) | 2007-11-15 |
KR20080106946A (ko) | 2008-12-09 |
MX2008012279A (es) | 2008-10-08 |
IL193842A0 (en) | 2011-08-01 |
AR060228A1 (es) | 2008-06-04 |
AU2007233237A1 (en) | 2007-10-11 |
NO20084546L (no) | 2008-12-23 |
US20100239568A1 (en) | 2010-09-23 |
CA2647430A1 (fr) | 2007-10-11 |
TW200806322A (en) | 2008-02-01 |
RU2008142775A (ru) | 2010-05-10 |
WO2007115045A3 (fr) | 2008-04-03 |
ZA200807590B (en) | 2009-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30348B1 (fr) | Diagnostics et traitements de tumeurs | |
CY1124144T1 (el) | Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης | |
MA31150B1 (fr) | Antagonistes spécifiques de vegf pour thérapie par adjuvant et néoadjuvant et traitement de tumeurs de premier stade | |
UA106194C2 (ru) | Диагностика и лечение рака с применением антитела к ereg | |
EP1912674A4 (fr) | Molécules d'anticorps fv à chaîne unique bispécifiques et procédés d'utilisation de celles-ci | |
MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
IL184617A (en) | Antibody against dr5 that includes mutations in the heavy and light chain of the full-length antibody 16e2 and various aspects related to this antibody | |
MX2009012625A (es) | Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21. | |
NZ592215A (en) | c-MET ANTIBODIES | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
MA30654B1 (fr) | Therapie tumorale avec anticorps anti-vegf | |
MY191348A (en) | Antibodies and derivatives thereof | |
TW200603828A (en) | Treatment of disorders | |
EA201291260A1 (ru) | Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo | |
SG170728A1 (en) | Anti-tumor cell antigen antibody therapeutics | |
MX340724B (es) | Terapia anti-angiogenesis para el tratamiento del cancer de mama. | |
TW200716141A (en) | Compositions and methods for treatment for neoplasms | |
EA201071421A1 (ru) | Анти-flt3 антитела | |
AR058325A1 (es) | Anticuerpos anti mn y metodos para su utilizacion | |
GB0724532D0 (en) | Trail variants for treating cancer | |
MA34059B1 (fr) | Thérapie anti-angiogénique pour le traitement du cancer des ovaires | |
ATE502052T1 (de) | Monoklonale antikörper gegen den humanen anti- müllerian-hormonrezeptor vom typ ii (amhr-ii) | |
MX2009005058A (es) | Metodos para tratar, diagnosticar o detectar cancer. | |
CY1112288T1 (el) | Θεραπεια του καρκινου με αντισωματα κατα της il-1a | |
TNSN08401A1 (en) | Methods of treating diagnosing or detecting cancer |